Drugs / JNJ-101556143
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06095089 | Nov 2023 → Jun 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05818683 | Apr 2023 → Aug 2027 expected | prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06800313 | Feb 2025 → Apr 2028 expected | metastatic prostate carcinoma | Halda Therapeutics OpCo, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-101556143 | “Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer” NCT06800313 ↗ |
| Known as | HLD-0915 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06800313 ↗ |
| Route | Oral | “safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of oral single-agent HLD-0915” NCT06800313 ↗ |